Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in the prevention and treatment of gastrointestinal (GI) disorders. The Company’s products are APRISO (mesalamine) indicated for the maintenance of remission of ulcerative colitis; COLAZAL (balsalazide disodium), treats mildly to moderately active ulcerative colitis, a form of inflammatory bowel disease with symptoms including bloody diarrhea and rectal bleeding; FULYZAQ (crofelemer) is an anti-diarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO (balsalazide disodium) is indicated for the treatment of mildly to moderately active ulcerative colitis (UC) in male patients 18 years of age and older; METOZOLV (metoclopramide HCl) ODT is orally disintegrating metoclopramide tablet, indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (gastric stasis) in adults; among others.